Aristocrat Leisure (ASX:ALL) Share Price Crosses Above Two Hundred Day Moving Average of $0.00

Share on StockTwits

Aristocrat Leisure Limited (ASX:ALL)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.00 and traded as high as $30.07. Aristocrat Leisure shares last traded at $29.61, with a volume of 1,657,968 shares changing hands.

The firm’s 50-day moving average is A$29.92. The company has a debt-to-equity ratio of 156.46, a quick ratio of 1.46 and a current ratio of 1.62. The stock has a market capitalization of $18.91 billion and a price-to-earnings ratio of 29.91.

The company also recently disclosed a Interim dividend, which was paid on Tuesday, July 2nd. Stockholders of record on Tuesday, July 2nd were given a $0.22 dividend. This represents a dividend yield of 0.75%. The ex-dividend date was Wednesday, May 29th. Aristocrat Leisure’s dividend payout ratio is presently 44.44%.

In other Aristocrat Leisure news, insider Trevor Croker 116,390 shares of the firm’s stock in a transaction dated Wednesday, June 12th.

Aristocrat Leisure Company Profile (ASX:ALL)

Aristocrat Leisure Limited, together with its subsidiaries, engages in the development, assembly, sale, distribution, and servicing of games and systems in the Americas, Australia, New Zealand, and internationally. The company offers gaming content; and platforms and systems, including electronic gaming machines, casino management systems, and digital social games, as well as Web and mobile gaming services.

See Also: Liquidity

Receive News & Ratings for Aristocrat Leisure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aristocrat Leisure and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine
Unum Therapeutics  Price Target Lowered to $13.00 at Wedbush
Unum Therapeutics Price Target Lowered to $13.00 at Wedbush
Zendesk  Research Coverage Started at Compass Point
Zendesk Research Coverage Started at Compass Point
Afya  Coverage Initiated at Bank of America
Afya Coverage Initiated at Bank of America
Telefonica  Downgraded to “Neutral” at Bank of America
Telefonica Downgraded to “Neutral” at Bank of America


 
© 2006-2019 Zolmax.